Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure-Reference-Cited by-同舟云学术

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

Published:2016-09-01 Issue:9 Volume:128 Page:1246-1259
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Mossner Maximilian¹,Jann Johann-Christoph¹,Wittig Janina¹,Nolte Florian¹,Fey Stephanie¹,Nowak Verena¹,Obländer Julia¹,Pressler Jovita¹,Palme Iris¹,Xanthopoulos Christina¹,Boch Tobias¹,Metzgeroth Georgia¹,Röhl Henning²,Witt Stephanie H.³,Dukal Helene³,Klein Corinna⁴⁵,Schmitt Steffen⁶,Gelß Patrick⁷,Platzbecker Uwe⁸,Balaian Ekaterina⁸,Fabarius Alice¹,Blum Helmut⁹,Schulze Torsten J.¹⁰,Meggendorfer Manja¹¹,Haferlach Claudia¹¹,Trumpp Andreas⁴⁵¹²,Hofmann Wolf-Karsten¹,Medyouf Hind¹⁴⁵¹³,Nowak Daniel¹

Affiliation:

1. Department of Hematology and Oncology,

2. Department of Orthopedics, and

3. Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany;

4. Division of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany;

5. German Cancer Consortium, Heidelberg, Germany;

6. Imaging and Cytometry Core Facility, German Cancer Research Center, Heidelberg, Germany;

7. Department of Mathematics and Computer Science, Freie Universität Berlin, Berlin, Germany;

8. University Hospital Carl Gustav Carus, Dresden, Germany;

9. Laboratory for Functional Genome Analysis, Gene Center, Munich, Germany;

10. Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, University of Heidelberg, German Red Cross Blood Service, Baden-Württemberg–Hessen, Germany;

11. Munich Leukemia Laboratory, Munich, Germany;

12. Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany; and

13. Georg-Speyer Haus Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany

Abstract

Key Points Mutational trajectories are defined by complex patterns of molecular heterogeneity in MDS, including lower-risk cases. Therapeutic intervention dynamically reshapes mutational patterns often resulting in branched or independent evolution of MDS clones.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/9/1246/1398739/1246.pdf

Reference49 articles.

1. Mutation in TET2 in myeloid cancers.;Delhommeau;N Engl J Med,2009

2. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.;Gelsi-Boyer;Br J Haematol,2009

3. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.;Kon;Nat Genet,2013

4. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.;Papaemmanuil;N Engl J Med,2011

5. Frequent pathway mutations of splicing machinery in myelodysplasia.;Yoshida;Nature,2011

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SintraREViewed: practice changing, or validation required?;The Lancet Haematology;2024-09

2. Molecular Pathology of Myeloid Neoplasms;Clinics in Laboratory Medicine;2024-06

3. Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes;Blood Advances;2024-05-17

4. Advances in the management of higher-risk myelodysplastic syndromes: future prospects;Leukemia & Lymphoma;2024-05-07

5. A mitochondrial surveillance mechanism activated by SRSF2 mutations in hematologic malignancies;Journal of Clinical Investigation;2024-05-07